FDA Clears C2N Blood Test for Alzheimer’s Detection in Patients Over 40

The authorization follows nearly two decades of financial backing from the Alzheimer’s Drug Discovery Foundation (ADDF), which provided early seed funding to C2N in 2008. The test joins a rapidly expanding market for blood-based diagnostics, with three such tools gaining FDA approval in just over a year. ADDF Chief Executive Officer Isobel Coleman noted that this rapid progression validates the importance of sustained investment in translational science, moving concepts from laboratory research into standard clinical practice.

Alzheimer’s pathology often develops 15 to 20 years before clinical symptoms manifest. By enabling detection in patients in their 40s and 50s, the PrecivityAD2 test aims to bridge this diagnostic gap. The tool is expected to improve the precision of clinical trials and support the development of tailored combination therapies. Currently, 83% of active Alzheimer’s clinical trials incorporate biomarker assessment, a trend that Laura Nisenbaum, the ADDF’s Interim Chief Science Officer, compares to the highly targeted diagnostic approaches used in modern oncology. The ADDF, which has funded 792 research programs globally, continues to manage a portfolio of 47 active diagnostics projects aimed at identifying tau proteins and other mixed pathologies.